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Abstract
Objective Inflammatory and metabolic pathways are implicated in preterm birth and preeclampsia. However, studies rarely
compare second trimester inflammatory and metabolic markers between women who deliver preterm with and without
preeclampsia.
Study design A sample of 129 women (43 with preeclampsia) with preterm delivery was obtained from an existing
population-based birth cohort. Banked second trimester serum samples were assayed for 267 inflammatory and metabolic
markers. Backwards-stepwise logistic regression models were used to calculate odds ratios.
Results Higher 5-α-pregnan-3β,20α-diol disulfate, and lower 1-linoleoylglycerophosphoethanolamine and octadecanedio-
ate, predicted increased odds of preeclampsia.
Conclusions Among women with preterm births, those who developed preeclampsia differed with respect metabolic mar-
kers. These findings point to potential etiologic underpinnings for preeclampsia as a precursor to preterm birth.
Introduction
Preeclampsia is a gestation-specific syndrome, defined by
the presence of hypertension combined with proteinuria or
evidence of systemic disease that presents after 20 weeks
gestational age (GA) [1]. Affecting 2−8% of pregnancies,
preeclampsia is a major cause of maternal mortality [2]. The
only current treatment is induction of labor, resulting in
increased risk for preterm birth, perinatal death, and neo-
natal complications [2].
Although the etiology of preeclampsia is still poorly
understood, it is considered to be a vascular disorder caused
by distress signals released by an ischemic placenta [1].
Similar to nonpregnancy vascular and cardio-metabolic
disorders, e.g. atherosclerosis and metabolic syndrome,
preeclampsia is believed to have etiological roots in
inflammatory and metabolic disturbances [1]. Metabolomic
analyses of blood and urine collected from women with
preeclampsia versus healthy pregnancies have identified
several potential metabolic pathways implicated in pre-
eclampsia, including insulin resistance, mitochondrial dys-
function, energy metabolism disturbances, oxidative
dysfunction and lipid dysfunction [3–15]. Although less
studied, the evidence supports preeclampsia as a proin-
flammatory state [16–23]. However, most studies of
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inflammatory activity in preeclampsia have been conducted
either following diagnosis or, if prior, they examined only a
few inflammatory markers (e.g. C-reactive protein, inter-
leukin (IL) 6, neutrophil gelatinase-associated lipocalin,
tumor necrosis factor (TNF) α, vascular cellular adhesion
molecule-1) [18, 19] (for exceptions, see refs. [21, 24]).
Similar to preeclampsia, preterm birth, i.e. <37 weeks
GA, could have roots in metabolic and inflammatory dis-
turbances, e.g. placental damage or vascular lesions [25].
Previous studies have focused on differences in metabolic
and inflammatory activity between women with healthy
pregnancies and women with either preeclampsia or who
delivered preterm. Few studies have assessed early preg-
nancy inflammatory and metabolic differences between
women who delivered preterm and who delivered preterm
with preeclampsia. Indeed, only one study was found that
examined metabolic differences between four women who
developed preeclampsia and five women who delivered
preterm. Distinct second trimester serum phospholipid
profiles by pregnancy outcome were observed, but the study
(n= 9) was not sufficiently powered to characterize those
differences [14]. No studies were found that evaluated
inflammatory marker differences between women who
delivered preterm with or without preeclampsia. Investi-
gating the early pregnancy differences in metabolic and
inflammatory markers between women who later delivered
preterm with or without preeclampsia could contribute to
our understanding the inflammatory and metabolic etiologic
divergences between these adverse pregnancy outcomes.
The aim of this study was to examine differences in mid-
pregnancy inflammatory and metabolic markers between
women who delivered preterm (<37 weeks GA) with or
without preeclampsia. Given differing phenotypes, we
hypothesized that women with preterm birth and pre-
eclampsia would exhibit different immune and metabolic
profiles compared to GA-matched women delivering pre-
term without preeclampsia.
Methods
Preeclampsia and non-preeclampsia groups
The sample of 129 women was drawn from a population-
based cohort of singleton California births (July 2009 to
December 2010), which is described in detail elsewhere
[26]. Briefly, all women had mid-pregnancy nonfasting
serum samples (15−20 weeks’ gestation) banked by the
California Biobank Program following protocols used for
routine prenatal screening for aneuploidies and neural tube
defects by the California Genetic Disease Screening Pro-
gram. Fetuses with a known congenital anomaly were
excluded from the analysis. Detailed demographic and
obstetric information were obtained from a linked hospital
discharge birth cohort database maintained by the California
Office of Statewide Health Planning and Development
(OSHPD). The final source set for this study included 496
women with deliveries before 37 weeks, with fortification
for deliveries before 32 weeks.
Within this cohort, 43 women delivered preterm
(<37 weeks GA) and had a diagnosis of preeclampsia in the
hospital discharge record for their delivery. International
Classification of Diseases, Ninth Revision, Clinical mod-
ification (ICD-9-CM) criteria was used for coding (642.4
(mild), 642.5 (severe), and 642.7 (superimposed on pre-
existing hypertension)). These cases were matched by GA
at a ratio of 2:1 with 86 women who delivered preterm but
without a preeclampsia diagnosis.
Serum inflammatory and metabolic markers
Banked serum samples were stored in 1mL tubes at −80 °C
prior to assay. Metabolic profiling was performed by Meta-
bolon, Inc., a commercial supplier of global metabolomics
data. Briefly, three sample extracts were used for chromato-
graphy/mass spectrometry (LC/MS, Waters ACQUITY
UPLC and Thermo-Finnigan LTQ mass spectrometer) in (1)
positive (acidic) and (2) negative (basic) ionization modes, as
well as (3) gas chromatography/mass spectrometry (GC/MS,
Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole
mass spectrometer). Peaks were identified via Metabolon’s
propriety peak integration software and compounds were
identified through comparison of library entries of purified
standards or recent unknown entities, with data normalization
to correct any variation due to instrument inter-day tuning
differences. Metabolic marker concentrations were trans-
formed by dividing by the cohort sample median for that
metabolite. As such, values less than “1” indicate metabolite
concentrations less than the cohort median. Given previous
work documenting preeclampsia-associated disturbances in
lipids, carbohydrates and energy metabolites, we focused on
198 metabolites [3–15].
Samples were assayed for 63 inflammatory markers
(including interleukins, interferons, chemokine ligands,
TNFα family cytokines, growth factors, colony-stimulating
factors, soluble adhesion molecules) at the Human Immune
Monitoring Center (HIMC; Stanford University), using
human multiplex kits (custom-built by eBioscience, San
Diego, CA) and read using a Luminex 200 instrument
(Austin, TX) in accordance with the manufacturer’s
recommendations. Protocol details have been described
elsewhere [27]. Median fluorescence intensity values were
reported for all inflammatory markers using Masterplex
software (Hitashi Solutions, San Bruno, CA). All inter-
assay coefficients (CVs) were <15% across all markers, and
all intra-assay CVs were <10%.
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Adiponectin, leptin, and a series of lipids (total choles-
terol, low-density lipoprotein (LDL), high-density lipopro-
tein, and triglycerides) were assayed at the State Hygienic
Laboratory (University of Iowa) using a Roche Diagnostics
c111 Cobas Analyzer (Basel, Switzerland). Total choles-
terol and LDL levels were converted to multiples of the
median. A total of 267 inflammatory and metabolic markers
were available for analysis (Supplemental Table 1).
Covariates
Maternal characteristics were included as covariates, and were
obtained from birth certificate record and hospital discharge
ICD-9 records. Characteristics obtained from birth certificate
records included: race or ethnicity (Black, Hispanic, Asian or
“other” race/ethnicity versus White non-Hispanic), maternal
age at delivery (“less than 18 years” or “more than 34 years”
versus “18 to 34 years”), maternal education (“less than 12
years” or “more than 12 years” versus “12 years or high
school”), payment for birth (public insurance for birth (Medi-
Cal, California’s Medicaid, health coverage for low-income
persons) versus not), parity (nulliparous versus multiparous),
nativity (maternal birthplace outside the US versus within the
US), smoked during pregnancy (report of any smoking versus
no report), previous preterm birth (previous preterm birth
versus none), and prepregnancy body mass index (BMI).
Maternal BMI was calculated from prepregnancy weight and
height. Women were categorized as underweight (less than
18.5 kg/m2), normal (18.5−24.9 kg/m2), overweight (25.0
−29.9 kg/m2), obese (30.0 kg/m2 or more) compared to nor-
mal BMI (18.5−24.9 kg/m2), with “normal” BMI being the
comparison group.
Maternal factors obtained from hospital discharge ICD-9
records included diabetes, drug or alcohol dependence/
abuse, mental illness, and anemia. Women were coded as
having “diabetes” if they had ICD-9 codes indicating any
form of diabetes or abnormal glucose tolerance (ICD-9s
648.0—Diabetes mellitus complicating pregnancy, child-
birth or the puerperium, 250—Diabetes mellitus, 648.8—
Abnormal glucose tolerance complicating pregnancy,
childbirth or the puerperium) and were compared to women
with no diabetes. Drug or alcohol dependence was indicated
in the presence of any ICD-9 code indicating drug or
alcohol use (ICD-9s 648.3—Drug dependence complicating
pregnancy, childbirth or the puerperium; 304—Drug
dependence; 305—Nondependent abuse of drugs, 303—
Alcohol dependence syndrome), and were compared to
women with no indication of drug or alcohol abuse. Women
were coded as having a mental illness (ICD-9 code 648.4—
Mental disorder complicating pregnancy, childbirth or the
puerperium) versus no mental illness. And women were
coded as having anemia (648.2—Anemia complicating
pregnancy, childbirth or the puerperium) versus not.
Analytic strategy
First, logistic regression was used to compare women with
and without preeclampsia on maternal characteristics and
each of the inflammatory and metabolic markers. Crude
odds ratios (OR) and 95% confidence intervals (95% CI)
were calculated (Supplemental Table 1). Maternal char-
acteristics and biomarkers with crude ORs of p < 0.2 were
retained for additional model building (see below).
Next, a multivariable model for preeclampsia was built
using backwards-stepwise logistic regression to calculate
OR for each maternal covariate and biomarker. All variables
with p < 0.20 in initial crude analyses were included in the
first step of the model. The backwards-stepwise logistic
regression then sequentially removes variables in order of
greatest p-value, re-running the model after each variable is
removed. Removal of variables continues until no addi-
tional variables can be removed without a significant loss of
model fit, and the final model included only variables with a
p < 0.05. Power analyses indicated that, given our sample
size and a logistic regression approach, our analyses are
capable of detecting ORs > 2.29 or ORs < 0.436 [27]. A
sample was created using cross-validation with replacement
using a replicate size of 10 to evaluate the replicability of
the multivariable model.
Results
Sample characteristics
Sample characteristics are presented in Table 1. Participants
were on average 29.9 ± 6.29 years old and predominately
Latina/Hispanic (52%) or non-Latina White/Caucasian
(33%). Approximately half (49%) of the sample were
receiving MediCal insurance. Women on average gave birth
at 32.4 ± 3.6 weeks GA. Women diagnosed with pre-
eclampsia had marginally higher prepregnancy BMI, t(127)
=−1.92, p= 0.057 (27.6 ± 7.57 kg/m2 versus 25.3 ± 5.85
kg/m2). There were no group differences at p < 0.05.
Model building
Three maternal characteristics differed (p < 0.2) between
women with and without preeclampsia and were included as
covariates in the multivariable model: mother born outside
of the United States, OR= 0.4, 95% CI (0.2, 0.9), obese
BMI, OR= 2.3, 95% CI (1.0, 5.7), and diabetes, OR= 2.3,
95% CI (1.0, 5.1). Of the biomarkers examined, two
inflammatory markers and 32 metabolic markers differed
between women with and without preeclampsia (p < 0.2)
and were also entered in the multivariable model (Supple-
mental Table 1).
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The final multivariable model included two significant
maternal covariates: Women born outside of the United
States were at lower odds of developing preeclampsia,
adjusted OR= 0.43, p= 0.048, 95% CI (0.19, 0.99), while
women with diabetes were at higher odds, adjusted OR=
2.80, 95% CI (1.14, 6.85). With respect to biomarkers, of
the two inflammatory and 32 metabolic markers, only four
metabolic markers significantly differentiated between
women who delivered preterm with or without preeclampsia
independent of covariates. Specifically, higher levels of 1-
linoleoylglycerophosphoethanolamine, adjusted OR= 0.29,
p= 0.007, 95% CI (0.12, 0.71), and octadecanedioate, OR
= 0.27, p= 0.021, 95% CI (0.09, 0.82), were associated
with reduced odds of preeclampsia. Elevated levels of 5-α-
pregnan-3β,20α-diol disulfate, adjusted OR= 2.74, p=
0.020, 95% CI (1.17, 6.38), and 5-HETE, adjusted OR=
1.30, p= 0.004, 95% CI (1.09, 1.54), were associated with
an increased odds of preeclampsia (Table 2).
In the cross-validation sample, of the two covariates,
only diabetes diagnosis predicted greater odds of a pre-
eclampsia. With respect to the four metabolic markers, only
three remained significant in the cross-validation sample.
Similar to the source sample, higher levels of 1-
linoleoylglycerophosphoethanolamine and octadecanedio-
ate predicted reduced odds of preeclampsia, and higher
levels of 5-α-pregnan-3β,20α-diol disulfate predicted higher
odds of preeclampsia (Table 2). In the cross-validation
sample, 5-HETE was not significantly associated with odds
of developing preeclampsia (Table 2).
Discussion
The purpose of this study was to compare second trimester
metabolic and inflammatory factors in preterm births with
and without preeclampsia. Independent of maternal char-
acteristics, we found that women who delivered preterm
with or without preeclampsia were more similar than dif-
ferent in terms of inflammatory and metabolic profiles at 15
−20 weeks gestation. However, of the 198 metabolic
markers, three emerged as differentiators between women
who did or did not develop preeclampsia. Specifically,
elevated second trimester serum levels of 5-α-pregnan-
3β,20α-diol disulfate, a progesterone metabolite, was asso-
ciated with higher odds of preeclampsia, and higher levels
of 1-linoleoylglycerophosphoethanolamine, a lysopho-
spholipid, and octadecanedioate, a long fatty acid chain,
with reduced odds of preeclampsia.
Our study found that lower levels of 1-
linoleoylglycerophosphoethanolamine in serum was asso-
ciated with greater odds of a preeclampsia. This finding is
consistent with previous research that reported significantly
lower levels of lysophospholipids in women who developed
preeclampsia compared to healthy, term pregnancies [28].
Lysophospholipids are lipid derivatives with one or both acyl
derivatives removed through hydrolysis, and the lysopho-
spholipid system plays a role in cell-to-cell signal transmis-
sion and regulates several aspects of reproduction and
parturition, including trophoblast function and placentation
[29]. Lower levels of 1-linoleoylglycerophosphoethanolamine
in second trimester serum in women who develop pre-
eclampsia may suggest early lysophospholipid system
dysregulation.
Higher levels of the progesterone metabolite, 5α-preg-
nan-3β, 20α-diol disulfate, during the second trimester were
associated with increased odds of developing preeclampsia.
This is consistent with past work that reported higher pro-
gesterone levels in the placenta and serum of women with
preeclampsia, or who developed preeclampsia, compared to
healthy, term controls [30–33] (for exceptions, see refs. [34,
35]). When healthy placentas are exposed to the levels of
progesterone obtained from placentas of women with pre-
eclampsia, pathways that promote vasoconstriction in the
placenta are activated [33], suggesting that increased
Table 1 Sample characteristics
Variable Full sample (n= 129) PE (n= 43) Non-PE (n= 86) p
Race/ethnicity
White 33% (43) 37% (16) 31% (27) 0.401
Latina 52% (67) 56% (24) 50% (43)
Asian 9% (12) 5% (2) 12% (10)
Black 2% (2) 0% (0) 2% (2)
Unknown 4% (5) 2% (1) 5% (4)
Age (years) 29.9 ± 6.29 30.4 ± 6.60 29.6 ± 6.15 0.490
Public insurance 49% (63) 44% (19) 51% (44) 0.455
Prepregnancy BMI 26.1 ± 6.53 27.6 ± 7.57 25.4 ± 5.85 0.057
GA at assessment (weeks) 16.4 ± 1.01 16.5 ± 1.10 16.3 ± 0.963 0.461
GA at birth (weeks) 32.4 ± 3.64 32.4 ± 3.67 32.4 ± 3.64 1.00
Delivery mode (C-section) 61% (79) 78% (33) 53% (46) 0.011
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progesterone metabolites indicates increased early vaso-
constriction in placentas of women who go on to develop
preeclampsia. As such, increased serum progesterone
metabolites may be an early indicator of placental pathology
in women who go on to develop preeclampsia.
In both the source sample and cross-validation sample,
lower levels of octadecanedioate were associated with an
increased odds of preeclampsia. Octadecanedioate is a fatty
acid not commonly found in humans [36]. One study
reported that octadecandioate has both antioxidant and
antidiabetic properties [37], which is consistent with the
association observed here between higher levels of octa-
decanediote and reduced risk for preeclampsia. No other
studies that we are aware of have considered octadecane-
dioate in the context of pregnancy. Future research is nee-
ded to determine how octadecanedioate levels in serum
might related to the etiology of preeclampsia in the context
of preterm birth.
We note that group differences were observed for
metabolic markers but not for inflammatory markers. These
data suggest that differences in metabolism may be the key
distinguishing processes between women who do and do
not develop preeclampsia in women with preterm birth.
These data also support previous research showing the
inflammation represents a common pathway in the emer-
gence of preterm birth with and without preeclampsia [24].
It is also possible that previously reported associations
between preeclampsia and greater inflammation may be due
to sample collection after preeclampsia diagnosis [16–23],
reflecting a secondary symptom of advanced preeclampsia
pathology rather than an etiological cause.
While this study is among the first to compare early
pregnancy differences in combined inflammatory and
metabolic activity between women who later deliver
preterm with or without preeclampsia, it has some lim-
itations. First, we had access to samples from only one
time point in pregnancy. There is evidence that inflam-
matory and metabolic activity changes over the course of
pregnancy [38, 39]. While we captured mean-level dif-
ferences early in pregnancy, it is also possible that rate of
or lack of change in inflammatory and/or metabolic
markers could be indicative of early pathological pro-
cesses [19]. Examining changes in markers over preg-
nancy may help differentiate between women who
develop preeclampsia versus those who do not. Second,
our sample was taken from a retrospective cohort study,
and we were restricted to data available in linked medical
records. Potentially valuable information, e.g. onset,
severity and history of preeclampsia, or type and cause of
preterm birth, was either not available or we were too
underpowered to consider these additional factors. Addi-
tional research in larger samples is needed to understand
how additional medical factors may be related to early
pregnancy inflammatory and metabolic activity. Finally,
due to our primary interest in etiological differences
between women who delivered preterm with or without
preeclampsia, a control group of women with healthy
pregnancies was not included. Future research should
explore how similarities or differences in mid-pregnancy
inflammatory and metabolic markers between women who
delivered preterm with or without preeclampsia compared
to healthy pregnancies.
In summary, while research has shown that inflammatory
and metabolic activity is involved in early etiology of both
preeclampsia and preterm birth in general [3–23, 25], no
studies to our knowledge have directly assessed potential
differences across these pathways in women who deliver
preterm with and without preeclampsia. Of the 267 meta-
bolic and inflammatory markers tested, only three were
associated with risk for preeclampsia in women with pre-
term birth, suggesting that overall women who deliver
preterm with and without preeclampsia have fairly similar
metabolic and inflammatory profiles in mid-pregnancy.
Risk for preeclampsia was, however, associated with
metabolic markers related to progesterone, lysopho-
spholipid and fatty acid metabolism, which may play an
etiologic role in the development of preeclampsia in women
with preterm birth. While findings require further investi-
gation, these data could allow for the early identification of
women at risk for preterm birth with preeclampsia and for
further inquiry into pathways that may be amenable to
intervention.
Table 2 Multivariable model
predicting pregnancy outcome
(preterm birth with or without
preeclampsia) from the four
mid-pregnancy serum metabolic
markers and adjusting for
diabetes diagnosis and birth
outside the US
Maternal factor Source sample Cross-validation sample
aOR (95% CI) p value aOR (95% CI) p value
Mother born outside US 0.43 (0.19, 0.99) 0.048 0.61 (0.35, 1.54) 0.298
Diabetes 2.80 (1.14, 6.85) 0.025 2.66 (0.91, 7.76) 0.073
1-linoleoylglycerophosphoethanolamine 0.29 (0.12, 0.71) 0.007 0.32 (0.12, 0.85) 0.022
Octadecanedioate 0.27 (0.09, 0.82) 0.021 0.32 (0.09, 1.06) 0.062
5-α-pregnan-3β,20α-diol disulfate 2.74 (1.17, 6.38) 0.020 2.72 (1.07, 6.95) 0.036
5-HETE 1.30 (1.09, 1.54) 0.004 1.14 (0.92, 1.41) 0.238
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